Nuveen LLC Takes $635,000 Position in Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• Nuveen LLC has acquired 59,978 shares of Arcturus Therapeutics, valued at approximately $635,000, representing a 0.22% ownership stake as of the most recent reporting period.
• Shares of Arcturus Therapeutics have shown significant price movement, with a 1-year low of $8.04 and a 1-year high of $25.88, recently opening at $17.19.
• Analyst ratings for Arcturus Therapeutics currently reflect a consensus of "Buy", with target prices ranging from $42.00 to $68.00 as multiple firms update their evaluations.

Nuveen LLC acquired a new stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 59,978 shares of the biotechnology company's stock, valued at approximately $635,000. Nuveen LLC owned 0.22% of Arcturus Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. ARK Investment Management LLC boosted its stake in Arcturus Therapeutics by 3.9% in the first quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company's stock valued at $21,270,000 after acquiring an additional 74,629 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Arcturus Therapeutics by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company's stock worth $18,521,000 after buying an additional 64,367 shares during the period. Woodline Partners LP lifted its position in shares of Arcturus Therapeutics by 3.5% in the fourth quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company's stock worth $13,693,000 after purchasing an additional 26,956 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in Arcturus Therapeutics in the 4th quarter valued at about $9,312,000. Finally, MPM Bioimpact LLC grew its position in shares of Arcturus Therapeutics by 109.5% during the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company's stock worth $7,805,000 after buying an additional 240,435 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Wells Fargo & Company cut their target price on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a report on Wednesday, July 2nd. HC Wainwright started coverage on Arcturus Therapeutics in a report on Thursday. They issued a "buy" rating and a $60.00 target price for the company. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Leerink Partners dropped their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating for the company in a report on Friday, August 22nd. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Arcturus Therapeutics currently has an average rating of "Buy" and an average price target of $50.57.

Arcturus Therapeutics Stock Down 0.3%

NASDAQ ARCT traded down $0.06 on Monday, hitting $17.79. The company's stock had a trading volume of 265,547 shares, compared to its average volume of 471,170. The company's 50-day moving average is $14.93 and its 200 day moving average is $13.34. The firm has a market cap of $483.18 million, a PE ratio of -7.96 and a beta of 2.38. Arcturus Therapeutics Holdings Inc. has a 1-year low of $8.04 and a 1-year high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.77. The company had revenue of $28.30 million for the quarter, compared to analyst estimates of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, equities analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.